Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

β-Catenin Regulates Exosomal OPN: A Fibrotic Feedback in CKD

Cyagen Technical Content Team | June 18, 2022
Explore Cd44-KO (C57BL/6NCya-Cd44em1/Cya) Mouse Model
Cd44-KO (C57BL/6NCya-Cd44em1/Cya) mouse model. Key genetic feature: Cd44 conventional knockout.
Explore Cd44-KO (C57BL/6NCya-Cd44em1/Cya) Mouse Model
Contents
01. Background: The Role of Exosomal N-Terminal Osteopontin (N-OPN) in Mediating Tubular-Fibroblast Communication and Renal Fibrosis 02. Roadmap of UUO Model and UIRI Model 03. Research Results: Tubule-Specific β-catenin Deletion Alleviates Renal Fibrosis by Regulating the Exosomal OPN/CD44 Axis 04. Summary: $\beta$-catenin Governs the Tubular-Fibroblast Communication via Exosomal OPN/CD44 Signaling to Promote Renal Fibrosis 05. Reference

In March 2022, the team of Professor Lili Zhou from Southern Medical University in China published a paper entitled “β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis” in the Journal of Extracellular Vesicles, the top impact factor (IF=25.841) journal in the field of exosome research.

This study found that exosome-mediated activation of the OPN-CD44 signaling axis is controlled by β-catenin signaling and plays a key role in renal fibrosis.

Exosome-mediated OPN-CD44 signaling axis controlled by β-catenin in renal fibrosis

Background: The Role of Exosomal N-Terminal Osteopontin (N-OPN) in Mediating Tubular-Fibroblast Communication and Renal Fibrosis

Chronic Kidney Disease (CKD) is characterized by the gradual loss of renal function and progression of renal fibrosis, and is a high-risk factor of end-stage renal disease (ESRD).

Tubular injury and peripheral fibroblast activation are the hallmarks of chronic kidney disease (CKD), suggesting intimate communication between the two types of cells. However, the underlying mechanisms remain to be determined. Exosomes, extracellular vesicles which play a role in shuttling proteins and other materials to recipient cells, may be involved.

Osteopontin (OPN) is an extracellular matrix glyco-phosphoprotein. Through binding with its receptor CD44 and integrin β3, OPN mediates cell adhesion, proliferation, invasion and apoptosis, and plays a role during tissue fibrosis. Full-length OPN has a molecular weight of approximately 70 kDa. In the diseased state, full-length OPN is often cleaved into an N-terminal fragment (∼50 kDa) and two C-terminal fragments (∼18 and ∼16 kDa). N-OPN could be the major active form to trigger a series of pathological changes. However, the role of N-OPN in kidney injury has not yet been investigated. Furthermore, the underlying mechanisms and modulating signals are poorly understood.

Roadmap of UUO Model and UIRI Model

Roadmap of UUO Model and UIRI Model

Research Results: Tubule-Specific $\beta$-catenin Deletion Alleviates Renal Fibrosis by Regulating the Exosomal OPN/CD44 Axis

To determine the potential role of β-catenin in regulating OPN/CD44 axis signaling in renal fibrosis, researchers generated conditional knockout mice in which the β-catenin gene is specifically disrupted in renal tubules using the Cre-loxP system. Tubule-specific β-catenin conditional knockout mice (Ksp-β-catenin−/−) were created by mating β-catenin floxed mice with Ksp-cre transgenic mice, which were purchased from Cyagen Biosciences. This approach generated a UUO model of renal fibrosis, which was evaluated with western blotting, immunofluorescence, immunohistochemistry, transcriptome sequencing, extraction of exosomes and other methods to confirm that deletion of β-catenin can alleviate renal fibrosis. β-catenin is an effective controller of exosomal OPN/CD44 axis signaling.

Tubule-specific ablation of β-catenin attenuates renal fibrosis through blocking exosomal OPN/CD axis signaling.
Figure 1. Tubule-specific ablation of β-catenin attenuates renal fibrosis through blocking exosomal OPN/CD axis signaling.

To discern the role of CD44 in renal fibrosis, Cyagen constructed global CD44 knockout mice (CD44−/−) for theresearchers. The efficacy of CD44 knockout was confirmed in the UIRI model (one of CKD models) by both immunohistochemistry and western blotting. To test the role of CD44 in renal fibrosis, we used Masson staining, western blotting and immunofluorescence, RNA sequencing to confirm that knockout of CD decreases kidney fibrosis in the UIRI model.

Knockout of CD44 decreases kidney fibrosis in UIRI model. [5]
Figure 2. Knockout of CD44 decreases kidney fibrosis in UIRI model. [5]

The CD44 null mice (CD44−/−) aged 6–8 weeks, on a C57BL/6N background, were also sourced from Cyagen Biosciences.

In a previous study, the research team found that renal tubule-derived exosomes can induce fibroblast activation through Shh signaling and lead to renal fibrosis [4]. In this study, we continued to explore the role of tubular-derived exosomes in renal fibrosis, and found that tubular cell-derived exosomes, OPN, played a central role in promoting renal fibrosis through CD44 signaling.

Tubular cell-derived exosomal OPN plays a central role in promoting renal fibrosis [5]
Figure 3. Tubular cell-derived exosomal OPN plays a central role in promoting renal fibrosis [5]

Summary: β-catenin Governs the Tubular-Fibroblast Communication via Exosomal OPN/CD44 Signaling to Promote Renal Fibrosis

With tubule-specific β-catenin conditional knockout mice (cKO mice) and CD44 knockout mice, the study reveals the mechanism of β-catenin regulating OPN/CD44 axis signaling in renal fibrosis. β-catenin is a master controller for tubular cells and interstitial fibroblast communication, which promotes exosome secretion and OPN expression in injured tubular cells. OPN is encapsulated in tubular cell-derived exosomes, and then transferred to interstitial fibroblasts and induces myofibroblast activation through binding to its receptor CD44, and urinary N-OPN serves as an indicative marker for CKD progression and renal fibrosis.

Working model. The schematic presentation depicts the potential mechanism by which exosomal OPN/CD44 axis meditates renal fibrosis.
Figure 4. Working model. The schematic presentation depicts the potential mechanism by which exosomal OPN/CD44 axis meditates renal fibrosis.

Reference

1. Guan, H., et al. 2020. Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes. Experimental Cell Research.

2. Bai, G., et al. 2020. Stimulation of THP-1 Macrophages with LPS Increased the Production of Osteopontin-Encapsulating Exosome. Int J Mol Sci.

3. Kaleta, B. 2019. The role of osteopontin in kidney diseases. Inflamm Res.

4. Liu X, et al. 2020. Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis. Kidney Int.

5. Shuangqin Chen, et al. 2022. β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. Journal of Extracellular Vesicles.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
In Vivo CAR-T Enters Clinical Validation: How It Works and What Comes Next
Beyond Subretinal Injections: How AI is Reshaping AAV Capsid Engineering for Retinal Gene Therapy
Why Eli Lilly is Targeting Nav1.8 and MNK for Next-Gen Pain Therapeutics
Mastering AAV Cardiac Delivery: Serotypes, Promoters, and Ready-to-Use Models
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research